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We have previously reported the generation of pseudotype virus from chimeric gene constructs encoding the ectodomain
of the E1 or E2 glycoprotein of hepatitis C virus (HCV) genotype 1a appended to the trans membrane domain and cytoplasmic
tail of the vesicular stomatitis virus (VSV) G protein. Sera derived from chimpanzees immunized with homologous HCV
glycoproteins neutralized pseudotype virus infectivity (L. M. Lagging et al., J. Virol. 72, 3539–3546, 1998). We have now
extended this study to further understand the role of HCV glycoproteins in pseudotype virus entry. Although a number of
mammalian epithelial cells were susceptible to VSV/HCV pseudotype virus infection, plaquing efficiency was different among
host cell lines. Pseudotype virus adsorption at low temperature decreased plaque numbers. Treatment of E1 or E2
pseudotype virus in media between pH 5 and 8 before adsorption on cells did not significantly reduce plaque numbers. On
the other hand, treatment of cells with lysosomotropic agents or inhibitors of vacuolar H1 ATPases had an inhibitory role on
virus entry. Concanavalin A, a plant lectin, exhibited neutralization of both HCV E1 and E2 pseudotype virus infectivity.
However, mannose binding protein, a C-type mammalian lectin, did not neutralize virus in the absence or presence of serum
complement. Pseudotype virus infectivity was only partially inhibited by heparin, a highly sulfated glycosaminoglycan, in a
saturable manner. Additional studies suggested that low-density lipoprotein receptor related molecules partially inhibit E1
pseudotype virus infectivity, while CD81 related molecules interfere with E2 pseudotype virus infectivity. A further under-
standing of HCV entry and strategies appropriate for mimicking cell surface molecules may help in the development of new
mic Prestherapeutic modalities against HCV infection. © 2000 Acade
INTRODUCTION
Hepatitis C virus (HCV) is an important cause of mor-
bidity and mortality worldwide, causing a spectrum of
liver disease ranging from an asymptomatic carrier state
to end-stage liver disease. The most important feature of
persistent HCV infection is the development of chronic
hepatitis in half of the infected individuals and the po-
tential for disease progression to hepatocellular carci-
noma (Saito et al., 1990; Alter et al., 1992; Tong et al.,
1995). Unfortunately, a number of important issues re-
lated to HCV-mediated disease progression are not well
understood. Furthermore, neither a vaccine nor any other
means of very effective therapy (McHutchison et al.,
1998) is available to control HCV.
HCV does not replicate efficiently in mammalian cells,
and the difficulty in obtaining cell-free infectious virus is
hindering efforts to study the entry of HCV into cells.
Thus, it is not a straightforward exercise to characterize
the functions of the viral surface proteins in infection.
Further, the nature of host immune responses and the
mechanism by which HCV may evade neutralization
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have yet to be well understood. The selective interaction
of viruses with specific cell surface receptors is an es-
sential step in the initiation of a viral infection, and
different components of the host cell membrane can act
as viral receptors. This interaction often determines the
host range and cellular or tissue tropism of a virus and
therefore plays a role in determining virus pathogenicity.
However, tissue tropism appears to also be governed by
other factors such as virus stability or cell internal re-
striction rather than only the distribution of the cognate
receptor. The entry of an HCV genome during natural
infection may not lead to a productive infection in a wide
range of cells, as they are not permissive for HCV viral
gene expression, genome replication, and virus assem-
bly. The identification and isolation of specific cell sur-
face molecules which interact with HCV are important for
understanding their biology. We have generated a vesic-
ular stomatitis virus (VSV) HCV pseudotyped virus using
HCV chimeric glycoproteins modified for expression on
the mammalian cell surface, which allow incorporation
into the VSV envelope (Lagging et al., 1998). The
pseudotype virus generated either from E1 or from E2
exhibited infectivity to a number of mammalian cells.
Sera derived from chimpanzees immunized with the ho-
mologous HCV envelope glycoproteins neutralized
pseudotype virus infectivity. These results suggested a

























NS INpseudotype virus infectivity. A similar observation for the
functional role of HCV envelope glycoproteins was noted
using a recombinant VSV possessing the green fluores-
cent protein gene instead of the receptor-binding G pro-
tein gene (Matsuura et al., 1998). Since both of the
seudotype viruses enter into a number of mammalian
ells, HCV E1 and E2 appeared to have independent
nteractions with the cell surface of a broad host range
nder the experimental conditions used. Cells of differ-
nt types and species may therefore be susceptible to
nfectivity by HCV and have common cell surface recep-
ors which facilitate virus entry. However, this does not
ecessarily imply that HCV itself can replicate in those
ell lines shown to be susceptible to pseudotype virus
ntry. A recent observation of the compartmental distri-
ution of HCV quasispecies within peripheral blood cell
ubsets implicates extrahepatic replication of the virus
Afonso et al., 1999).
Pathogenic microorganisms may use carbohydrates
or carbohydrate-binding proteins to attach to or enter
host cells (Wick et al., 1991). Therefore, an attempt was
ade to determine whether the attachment of HCV E1
nd E2 may be mediated via the glycans that decorate
he E1 and E2 virus envelope glycoproteins. On the other
and, glycosaminoglycans (GAGs) commonly found on
he cell surface may also play a role in virus entry by
ecognizing GAG-binding motifs present in viral glyco-
roteins, and these motifs have been suggested to be
resent on HCV (Chen et al., 1997). The binding of HCV
2 to the major extracellular loop of CD81, a tetraspanin
xpressed on various cell types, may also play a role in
CV infectivity (Pileri et al., 1998). The available informa-
tion on the association of HCV with LDL or vLDL frac-
tions (Miyamoto et al., 1992; Thomssen et al., 1993; Kanto
et al., 1994; Prince et al., 1996; Seipp et al., 1997; Agnello
and Abel, 1997; Agnello et al., 1999) and the susceptibility
of a large number of cell lines to pseudotype virus infec-
tion (Lagging et al., 1998) allow for the speculation that a
wide-spread receptor related molecule may be a target
for virus entry (Agnello and Abel, 1997; Seipp et al., 1997).
This speculation further raises a question as to whether
both the E1 and the E2 pseudotype viruses recognize
identical or distinct cell surface receptors to promote
virus entry.
The mechanism of HCV entry into mammalian cells is
not known at this time. VSV pseudotype virus bearing
HCV ligands may be utilized as a tool for assessing the
role of cellular receptor–virus interactions, as has been
utilized for a number of other viruses (Clapham et al.,
1984; Dalgleish et al., 1984; Owens and Rose, 1993;
Schnell et al., 1996). VSV/HCV pseudotypes appear to be
able to enter into mammalian cells by an independent
interaction of either the E1 or the E2 envelope glycopro-
teins with the cell surface. Since VSV has a wide host
ROLE OF HCV GLYCOPROTEIrange for replication, entry of its genome from the
pseudotype virus allows replication of VSV in host cells.Defining how viruses interact with the cell surface is
important for explaining the pathogenesis of HCV. In this
study, pseudotype virus attachment and entry were ex-
amined by a number of different approaches to under-
stand the molecular mechanism of virus infection. Re-
sults suggested a complex and diverse interaction of the
E1 and E2 glycoproteins with cell surface moieties which
may enable HCV entry.
RESULTS
Characteristics of pseudotype virus plaque formation
VSV pseudotype virus entry into cells is likely initiated
by specific interactions of the HCV E1 and E2 glycopro-
teins with cell surface proteins. To begin to understand
the mechanism of virus entry, infectivity of pseudotype
virus bearing E1 or E2 was performed at 32°C in baby
hamster kidney (BHK) cells, human breast carcinoma
(MCF 7) cells, and human hepatoma (HepG2) cells. Re-
sults from these studies suggested that pseudotype vi-
rus entry is mediated separately by either of the two HCV
chimeric glycoproteins. To determine the comparative
plaquing efficiency of the pseudotype E1 or E2 in human
cell lines, inoculum of a predetermined titer of ;100 pfu
in BHK cells was used, with wild-type VSV as a control
for comparison. Plaque numbers observed with
pseudotypes bearing E1 or E2 in human cells (MCF 7
and HepG2) were similar and ;100–150% greater (Fig. 1)
than those seen in cells of nonhuman origin (BHK). A
similar analysis with wild-type VSV suggested titers of
approximately 20% less in MCF7 and 90% less in HepG2
FIG. 1. Plaquing efficiency of VSV pseudotypes bearing HCV E1 or E2
in mammalian cells. Three different cell types (BHK, MCF7, and HepG2)
were separately infected with pseudotype virus bearing HCV E1, E2, or
VSV as a control for comparison in an identical manner. Plaque assay
was done at 32°C and the results are presented from at least three
different assays as the mean values together with the standard devi-
ations for each assay.
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ASU, Awhich appears to be due to a slower replication effi-
ciency for the VSV genome in these two cell lines. The
information derived from these experiments allowed us
to normalize each virus inoculum to a set number of
plaques with regard to each cell line. The differences in
plaque number between pseudotypes bearing E1 or E2
and the wild-type VSV in human and nonhuman cells
may be related to the nature of the cell surface proteins
or receptors interacting with the E1 or E2 glycoproteins.
In a different experiment, when viruses were adsorbed at
4°C, a 7-fold reduction of virus titer with E1 and a 12-fold
reduction with E2 pseudotypes were observed in all
three cell lines. However, in a parallel experiment with
nonpseudotype VSV G (negative control), only a minor
change (#10%) in plaque number was observed. The
reductions in pseudotype virus titer with E1 or E2 with a
change in adsorption temperature from 32 to 4°C sug-
gested an energy-dependent virus interaction with the
cell surface. This dependence may also be associated
with a requirement for a temperature-sensitive confor-
mational change in E1 and E2 prior to adsorption.
HCV E1 and E2 pseudotype viruses were separately
analyzed to determine the time necessary to achieve
maximum adsorption at 32°C, and VSV was used as a
control. For this purpose, a predetermined virus titer was
added as inoculum on BHK cells and adsorbed for dif-
ferent time points. After adsorption at each time point,
the monolayer was washed extensively and an agar
overlay was added for plaque formation. Results from
this study suggested that the E1 pseudotype virus re-
quires approximately 10–15 min to complete adsorption,
whereas the E2 pseudotype virus required a slightly
FIG. 2. Kinetics of pseudotype virus attachment on BHK cells.
Pseudotype virus bearing HCV E1, E2, or VSV as a control were
adsorbed at 32°C on cells for the indicated time points. Cells were
washed three times with DMEM to remove virus inoculum and overlaid
with agar for plaque formation. Mean values and standard deviations
from three different experiments are shown.
216 MEYER, Blonger period of 20–30 min to complete adsorption, sim-
ilar to the VSV control (Fig. 2).Influence of pH on pseudotype virus attachment and
penetration
Many pH-dependent enveloped viruses are rapidly
and irreversibly inactivated by treatment with an acid
medium. To determine the effect of pH on virus inactiva-
tion prior to infection, a known titer of the virus inoculum
was incubated in media of different pH for 60 s. After
exposure, the medium was immediately adjusted to ;pH
7.0 and the inoculum was added onto the cell monolayer
for plaque assay. Results suggested that the pseudotype
virus generated from E1 or E2 exhibit a similar tolerance
within a range of pH 5.0–8.0 (Fig. 3). On the other hand,
nonpseudotype VSV G or wild-type VSV was inactivated
upon exposure to a mildly acidic pH #6.0 under these
experimental conditions. This observation on VSV is in
accordance with one described earlier (McClure et al.,
1990) and further illustrates the difference between the
pseudotyped virus and nonpseudotype or wild-type VSV.
Alterations to protein conformations which are in-
duced by low pH exposure can be alleviated by treat-
ment with lysosomotropic weak bases and ionophores
(Mellman et al., 1986). These agents act indirectly by
raising the intravascular pH. Inhibition of pseudotype
virus penetration by weak lysosomotropic bases may
give evidence which indicates that a virus requires low
pH for entry and delivery of its genome into the cells
(Marsh and Helenius, 1989). The effect of a weak base
on pseudotype virus infection was determined by treat-
ment of BHK cells with NH4Cl. Exposure of cells with
NH4Cl (30 mM) during the first 3 h of virus adsorption
ignificantly reduced virus titer (75%) of E1 and E2 com-
ared to an untreated control virus incubated in an iden-
ical medium (Table 1). The members of the Poxviridae
amily are thought to fuse their external lipid envelopes
irectly with the plasma membrane, liberating the ge-
ome into the cell interior (Doms et al., 1990; Vander-
FIG. 3. Effect of pH on virus titer. Virus inoculum was treated in
medium containing HEPES–HCl buffer of different pH for 1 min before
the addition of 1 M NaOH to bring the medium to neutral pH. Virus was
titrated in BHK cells and the plaque numbers are shown as the mean



































NS INplasschen et al., 1998). Intracellular vaccinia virus (VV)
was used in this study as a negative control for inhibition
of virus entry with lysosomotropic agents. Treatment of
cells with ammonium chloride did not significantly re-
duce VV entry (,10%) when tested in a manner similar to
pseudotype virus. On the other hand, viruses initially
binding to cell surface may be endocytosed and trans-
ported to the endosomal and lysosomal compartments,
where the viral fusion proteins are activated by exposure
to the low pH milieu of these compartments. Viruses
belonging to the Rhabdoviridae family typically require a
low pH-mediated event for efficient cell fusion and be-
long to this second category (Hernandez et al., 1996).
VSV was included as a positive control and treatment
with ammonium chloride significantly reduced (.80%)
plaque numbers.
Earlier studies on Sendai virus, known to enter cells by
direct fusion of the viral envelope with the plasma mem-
brane, exhibited an inhibition of infection upon exposure
to lysomotropic agents. This may be due to the side
effects that these compounds have on cellular metabo-
lism (Skehel et al., 1978; Seglen, 1983). Although agents
such as weak amines or ionophores disrupt the H1
gradient of endosomes, these agents should leave the
H1 pump functioning. Macrolide antibiotics, concanamy-
cin A and bafilomycin A1, are highly selective inhibitors of
the vacuolar H1-ATPase, blocking the acidification of
ndosomes (Bowman et al., 1988; Dro¨se et al., 1993;
oshimori et al., 1991). Our results from concanamycin A
r bafilomycin A1 treatment suggest that these two drugs
ignificantly modify the titer of the pseudotype virus bear-
ng the E1 or E2 glycoproteins in a dose-dependent
anner in MCF7 or BHK cells (Table 1). Concanamycin A
t a concentration of 1000 nM as an average reduced 62
TABLE 1
Inhibition of Pseudotype Virus Plaque Formation




% Reduction in plaque
numbera
E1 E2
NH4Cl 30 mM 78 6 3 76 6 2
10 mM 35 6 5 40 6 3
oncanamycin A 1000 nM 69 6 4 94 6 5
250 nM 36 6 8 68 6 10
50 nM 9 6 3 6 6 4
Bafilomycin A1 250 nM 97 6 3 99 6 0.7
100 nM 95 6 2 98 6 0.3
25 nM 34 6 2.6 58 6 1.2
Note. 6, Standard deviations.
a Percentage reduction is the mean value from at least three different
xperiments.
ROLE OF HCV GLYCOPROTEInd 86% of E1 and E2 plaque numbers, respectively. A
ourfold decrease of the drug concentration (250 nM)ignificantly reduced its ability to affect E1 pseudotype
ptake, compared to its relatively higher effect on the E2
seudotype. A similar treatment of the cell monolayer
ith bafilomycin A1 at concentrations between 25 and
50 nM exhibited an inhibitory effect on plaque number,
lthough at the lower concentration (25 nM) the effect
as slightly higher on E2 compared to E1. Identical
reatment of VV with concanamycin A did not significantly
educe plaque numbers (,10%) regardless of the con-
entration used. However, concanamycin A significantly
educed VSV titer (;75%). Our results with BHK and
CF7 cells were very similar, the only significant varia-
ion coming with regard to concanamycin A treatment. In
his case, exposure to this antibiotic resulted in a notice-
bly higher level of reduction in plaque number on
reated MCF7 cells compared to BHK. Exposure to this
ntibiotic resulted in a smaller plaque size in either cell
ine and an ;25% greater decrease in plaque number for
oth E1 and E2 in MCF7 cells.
ole of carbohydrates in pseudotype virus entry
Pathogenic microorganisms may use carbohydrates
r carbohydrate-binding proteins to attach to or enter
ost cells (Wick et al., 1991). HCV E1 and E2 are glyco-
sylated proteins with numerous potential N-glycosylation
sites within the predicted amino acid sequences (Choo
et al., 1991). The E2 glycoprotein has 11 N-linked poten-
tial glycosylation sites, and E1 has been shown to utilize
4 of the 5 glycosylation sites present (Meunier et al.,
1999). In addition to other sugar moieties, mannose is
present on both the E1 and the E2 glycoproteins. The
carbohydrates of the HCV envelope glycoproteins may
play a role in the initial step of HCV infection. To inves-
tigate a possible role for the carbohydrate components,
we tested the effect of a number of lectins of different
binding specificities in the neutralization of pseudotype
virus infectivity. A known titer of pseudotype virus or VSV
control was incubated with the lectins at 32°C for 1 h
before addition to the cell monolayer. Galanthus nivalis
agglutinin (GNA, recognizes }-D-mannosyl residues of
the nonreducing end) and phytohemagglutinin P (PHA-P,
recognizes oligosaccharides) exhibited an E1-specific
pseudotype virus neutralization (;40% for GNA and
;50% for PHA-P) at a relatively higher concentration (250
mg/ml). However, E2 pseudotype virus neutralization was
not observed under these conditions. In addition, treat-
ment of the cell monolayer with GNA, prior to virus
adsorption, did not effect the plaque number to any
extent for either pseudotype virus. Concanavalin A (Con
A), which binds to }-linked terminal mannose residues
on N-linked high-mannose or hybrid glycans, was most
effective in the neutralization of pseudotype virus bearing
E1 or E2 (Fig. 4). Con A neutralized pseudotype virus
217PSEUDOTYPE VIRUS ENTRYinfectivity in a dose-dependent manner (.25 mg/ml),














































ASU, Aside competitively inhibited virus neutralization. How-
ever, a lower concentration of Con A ($10 mg/ml) exhib-
ited an increase in plaque numbers of the pseudotype
virus in cells of human origin (HepG2 and MCF7) and the
plaque numbers were relatively higher with E2 compared
to the E1 pseudotype virus. The increase in virus plaque
number with the pseudotype virus may be related to a
bridging of the cells and the virus by Con A to achieve a
more proximal location to the cellular receptor and en-
hance virus entry. Indeed, treatment of the cell mono-
layer prior to virus adsorption suggested a similar finding
(data not shown). Treatment of wild-type VSV, which also
contains two N-linked glycosylation sites, with Con A (10
mg/ml) did not increase plaque numbers and exhibited a
dose-dependent neutralization activity. Addition of Con A
after virus adsorption had no detectable effect upon
pseudotype plaque number. These results suggest that
the inhibitory effect of Con A occurs by binding of the
viral envelope glycoproteins through mannose residues.
Neutralization apparent at lectin concentrations above 10
mg/ml may be incurred due to steric hindrance or an
alteration of envelope glycoprotein conformation, thereby
inhibiting pseudotype virus infectivity. Indeed, Con A has
been shown to strongly precipitate E1 and E2 recombi-
nant glycoproteins along with a high background of other
glycosylated proteins (Ralston et al., 1993) probably of
ellular origin. Mannose moieties present on mature
nvelope proteins may be recognized by cellular man-
ose receptors and mediate a specific cell entry (De-
raetere and Leroux-Roels, 1999). To examine this pos-
ibility, excess D-mannose or N-Ac-glucosamine was
dded before or together with virus inoculum for adsorp-
ion on cells at 4°C. The presence of excess sugar prior
o and during virus adsorption on cells did not signifi-
antly alter the plaque number. Therefore, specific rec-
FIG. 4. Dose-dependent effect of concanavalin A on pseudotype
virus plaque formation. A known virus titer (100 pfu) was treated with
different concentrations of Con A before addition to MCF7 cells. The
results are shown as the mean plaque numbers with standard devia-
tions from three different experiments.
218 MEYER, Bgnition of the complex mannose moieties associated
ith the E1 and E2 glycoproteins by the lectin-like pro-
t
seins present on cell surface does not appear to be
irectly related to virus entry.
Mannose binding proteins (MBP) are C-type lectins
hat circulate in the blood of mammals and possess a
arbohydrate binding specificity to glycoconjugates ter-
inating in mannose, fucose, glucose, or N-acetylglu-
osamine (Epstein et al., 1996). MBP is synthesized by
epatocytes and secreted into circulation at low levels,
ith its production increasing in response to stress and
nfection. MBP recognizes a wide range of microorgan-
sms and is also known to activate both the classical and
he alternate complement pathways. The potential role of
BP on pseudotype virus neutralization was investi-
ated by incubation with the pseudotype virus for 1 h at
2°C prior to addition on MCF7 cells. MBP did not
nhance or neutralize E1 or E2 pseudotype virus infec-
ivity between a concentration of 10 and 250 mg/ml. A
similar observation was noted when the cell monolayer
was first treated with MBP at 4°C prior to virus adsorp-
tion in the cold. In a separate experiment, pseudotype
virus was incubated with MBP at 37°C for 45 min in
DMEM supplemented with additional Ca21 (1, 2.5, or 5
mM final concentration). Guinea pig complement was
added to the virus/MBP mixture at a dilution of 1:20,
incubated at 37°C for an additional 15 min, and added to
an MCF7 cell monolayer for virus plaque formation at
32°C. A control experiment with complement alone was
tested similarly. E1 or E2 pseudotype virus titer was not
affected in the presence of MBP compared to a control
experiment with complement alone. These results sug-
gest that MBP does not interact in a manner similar to
Con A for virus neutralization or enhancement of virus
titer. MBP binds through a Ca21-dependent manner to
he terminal mannose equatorial 3-OH and 4-OH groups
Epstein et al., 1996) and also to complex and hybrid
ligosaccharides bearing terminal or subterminal
-acetyl glucosamine residues. It is likely that these
ites are not accessible to MBP in the HCV E1 or E2
lycoprotein. This may be of relevance in vivo for viral
ersistence as the endogenous sugar-binding lectin-like
rotein is known for its ability to act as a defense mech-
nism.
ole of cell surface proteoglycans in virus plaque
ormation
Proteoglycans and their attached glycosaminoglycans
ave a number of roles in cell–cell and cell–matrix inter-
ctions. These glycans bind a variety of structural pro-
eins, receptors, growth factors, and enzymes and play a
ole in the attachment of several microorganisms to
ammalian cells (Spear, 1993). A recent report has sug-
ested that suramin blocks HCV binding to human hep-
toma cells (Garson et al., 1999). To determine the po-
ND RAYential for the binding of HCV envelope glycoproteins to


























































NS INfate, heparan sulfate, and suramin were separately
tested at different concentrations. One of these com-
pounds, heparin, reduced the E2 plaque number by
;35% at a low concentration (1 mg/ml). Treatment with a
igher dose of heparin (20 mg/ml) revealed significant
eductions in both E1 and E2 pseudotypes of 30 and 60%,
espectively, in MCF7 cells (Fig. 5). A similar result was
bserved with HepG2 cells. A further increase in heparin
oncentration did not suggest an additional inhibitory
ffect on virus plaque formation. Reduction of the E1 or
2 plaque number in this assay appeared to be dose
ependent and saturable, although heparin at a lower
oncentration had a more pronounced effect on E2
laque formation. On the other hand, a higher quantity of
uramin was required to produce a significant inhibitory
ffect on E1 or E2 pseudotype virus plaque formation in
HK and MCF7 cells. In this assay, suramin at a concen-
ration of 500 mg/ml was required to inhibit the E1
seudotype plaque number to an extent greater than
0%, while the E2 pseudotype required a lesser concen-
ration (200 mg/ml) to achieve a similar result. The other
wo sulfated polysaccharides, dextran sulfate (500 mg/
ml) and heparan sulfate (250 mg/ml), did not have a
etectable inhibitory effect on pseudotype virus plaque
ormation in BHK or MCF7 cells.
Heparinase cleaves the glycosidic linkages present in
eparin. Treatment of MCF7 cells with heparinase (2
/ml) partially reduced the E2 pseudotype titer (27%
eduction) and was unable to inhibit E1 entry to any
iscernable level. The results suggest that an initial
ontact of VSV/HCV pseudotype virus may partly be
ade through sulfated polysaccharides present on the
FIG. 5. Dose-dependent inhibitory role of heparin on pseudotype
irus plaque formation. Virus was incubated with the indicated doses of
eparin for 1 h and added to an MCF7 cell monolayer for adsorption.
SV was included as a negative control. Cells were washed and
verlaid with agar for plaque formation. The mean values and standard
eviations from four different experiments are shown.
ROLE OF HCV GLYCOPROTEIell surface. This association appears to be stronger
ith the E2 pseudotype, as indicated by the cumulativeesults. Heparin may be required to increase the binding
f HCV envelope glycoproteins with the cell surface to a
econd receptor. Alternatively, binding with heparin may
nitiate changes in the envelope of the adsorbed virion
hich trigger entry through a different receptor.
ole of CD81 in the inhibition of pseudotype virus
nfectivity
To determine the role of cell surface CD81 molecule in
irus infectivity, a monoclonal antibody (JS-81) binding to
he extracellular domain of CD81 (Pharmingen) was used
n a pseudotype virus neutralization assay. MCF7 cells
ere incubated with serial dilutions of the JS-81 mono-
lonal antibody at 32°C for 30 min. Antibody was re-
oved and cells were extensively washed. Pseudotype
irus generated from E1 or E2 and VSV control of a
redetermined titer were added on antibody adsorbed
CF7 cells to assess virus infectivity. A monoclonal
ntibody of the same isotype (IgG1) to an unrelated
uman parainfluenza virus was used under identical
onditions as a negative control. Virus titers were deter-
ined by plaque assay as already described. Incubation
f cells with the monoclonal antibody (JS-81) to human
D81 (25 mg/ml), prior to pseudotype adsorption, de-
creased only the E2 pseudotype plaque number ;40%
(Table 2). A further increase in antibody concentration to
CD81 did not appreciably decrease the pseudotype
plaque number. A similar observation was also noted
when a recombinant CD81 was used in the neutralization
TABLE 2
Inhibition of Pseudotype Virus Plaque Formation




% Reduction in plaque
numberb
VSV E1 E2
mAb to hCD81 25 mg ,5 ,5 40 6 2
10 mg ,5 6 6 0.5 39 6 3
2.5 mg ,5 ,5 27 6 2
Recombinant CD81 25 mg ,5 ,5 40 6 6
10 mg ,5 0 38 6 4
5 mg ,5 0 30 6 3
Ab to LDL-R 500 mg ,5 23 6 4 ,5
250 mg ,5 20 6 2 ,5
125 mg ,5 6 6 2 ,5
LDL 150 mg ,5 50 6 2 ,5
75 mg ,5 48 6 4 ,5
40 mg ,5 39 6 1 ,5
Recombinant LDL-R354 25 mg ,5 43 6 7 9 6 2
10 mg ,5 42 6 8 ,5
5 mg ,5 21 6 0.2 ,5
Note. 6, Standard deviations.
a Experiments were done with ;106 cells/well.











































ASU, Aof virus infectivity (Table 2). In addition, none of these
reagents exhibited a significant inhibition (,10%) of VSV
plaque formation when used as a control. These results
further suggested that binding of E2 with CD81 may
indirectly facilitate virus entry.
Role of low-density lipoprotein receptor (LDL-R) in
pseudotype virus infectivity
The LDL-R is the patriarch of a family of cell surface
receptors that transport macromolecules into cells by
receptor-mediated endocytosis in clathrin-coated pits
(Brown et al., 1997). The sulfated glycosaminoglycan,
eparin, releases LDL from its receptor site on the sur-
ace of normal human fibroblasts. Heparin prevents the
inding of LDL to its receptor when added simulta-
eously with LDL to the fibroblast culture (Goldstein et
al., 1976). Ligand binding to LDL-R is destroyed by metal
ion chelators and restored by calcium (Goldstein and
Brown, 1974). Since LDL-R has been suggested to be a
candidate receptor for HCV entry (Agnello et al., 1999;
Monazahian et al., 1999), we first investigated the role of
a21 in pseudotype virus entry. Washing of HepG2 or
MCF7 cells with HBSS (without Ca21) and incubation
with EGTA (0.5, 1, or 2 mM) reduced plaque formation of
E1 or E2 pseudotype virus up to ;50% in a dose-depen-
dent manner. However, a further increase of EGTA con-
centration (.2 mM) disrupted the cell monolayer and did
not allow examination of its effect on plaque formation.
Thus, pseudotype virus entry appeared to be at least
partially dependent on the presence of Ca21 in the cul-
ture medium. A continuous uptake of LDL occurs due to
a recycling of the LDL receptor to the surface after its
dissociation from LDL within the cell. A monoclonal an-
tibody (mAb) to the LDL receptor (IgG-C7) reduces the
receptor binding of LDL, especially at 4°C (Beisiegel et
al., 1981). In this study, we have separately utilized mAb
to LDL-R, human LDL, and vLDL as the ligands for
blocking the LDL receptor. Ligands were incubated with
cells at 4°C for 30 min prior to addition of the pseudotype
virus to analyze any inhibitory effect on virus entry. Mab
to LDL-R (250–500 mg/106 cells) exhibited an ;23% re-
duction in E1 titer in both MCF7 and HepG2 cells (Table
2). On the other hand, LDL (40 mg/106 cells) or vLDL
(75–150 mg/106 cells) reduced ;45 and 50% of the E1
irus titer, respectively (Fig. 6 and Table 2). Additional
xperiments using pseudotype virus, previously incu-
ated with different doses of a recombinant LDL-recep-
or protein (LDL-R354), suggested an ;40% maximum
eduction of neutralization of E1 pseudotype virus infec-
ivity (Table 2). However, experiments with E2
seudotype failed to significantly reduce plaque number,
ndicating a role for LDL-R in E1 pseudotype virus entry.
220 MEYER, Barallel experiments with VSV as a control did not exhibit
significant reduction (,5%) in plaque numbers. oDISCUSSION
In this study, we have further expanded our earlier
bservations to understand the functional dichotomy of
he HCV individual glycoproteins. VSV pseudotype virus
earing HCV E1 or E2 glycoproteins may initiate infection
o different cell lines and exhibit significant cross inter-
erence by treatment with a number of agents. The use of
he pseudotype has allowed us to better understand the
imilar and divergent properties of those glycoproteins
hich are presumed to decorate the envelope of HCV.
Host-cell-determined routes of entry have been ob-
erved for enveloped viruses but the pH dependence is
sually a property of the virus envelope glycoproteins.
seudotype virus bearing HCV E1 or E2 is not irrevers-
bly inactivated upon exposure to a wide range of pH
rior to adsorption on cells. However, an alteration of
ndosomal pH inhibited virus infectivity. Enveloped vi-
uses in general enter into cells by the binding of virus to
eceptors on the cell surface followed by endocytosis of
he virion or by direct fusion of the virion envelope with
he cell plasma membrane (Lamb, 1993; Marsh and He-
enius, 1989). Viruses that require endocytosis for entry
ay undergo minimal interactions with the cell surface,
ufficient only to ensure that endocytosis occurs. The
iruses capitalize on the continuous cellular process of
ndocytosis for internalization and follow the same route
f entry as other macromolecules and physiological ef-
ectors, in order to obtain access to the cell interior
Wileman et al., 1985).
FIG. 6. Role of LDL in pseudotype virus infectivity. Prechilled MCF7
cells were incubated with different concentrations of LDL for 30 min at
4°C. Pseudotype virus or control VSV inoculum of known titer was
added to the cells and incubated for an additional 30 min. The cell
monolayer was washed with ice-cold DMEM, overlaid with agar, and
transferred to 32°C for plaque formation. The mean values and stan-
dard deviations from three different experiments are shown.
ND RAYAcidification of endosomes is achieved by the activity
f the vacuolar proton ATPase (v[H1]ATPase). This en-
NS INzyme pumps protons to the endosome interior at the
exposure of ATP hydrolysis, causing endosome acidifi-
cation within a few minutes. Acidification induces con-
formational changes in several animal virus glycopro-
teins so that the hydrophobic portions of the proteins
become more exposed, thereby increasing the tendency
of the protein to interact with membranes. The interac-
tion with the endosomal membrane leads to fusion of the
latter with the viral envelope, allowing for the release of
the viral nucleocapsid into the cellular cytoplasm, where
it is ready to initiate virus replication (reviewed in Guinea
and Carrasco, 1995). Flint et al. (1999b) recently sug-
gested the localization of a stretch of conserved hydro-
phobic amino acids within the E1 glycoprotein, which
display similarities to flavivirus and paramyxovirus fusion
peptides and may constitute the HCV fusion peptide.
Although, low-pH-associated conformational change(s)
in the E2 glycoprotein have been observed, neutral- or
low-pH treatment of CD81-positive cells expressing the
E2 chimeric glycoprotein at the cell surface does not
result in cell fusion (Flint et al., 1999a). Our experimental
observations indicate that cells treated with ammonium
chloride exhibit inhibition of pseudotype virus infectivity.
However, the effect of H1-ATPase inhibitors, bafilomycin
A1 or concanamycin A, was more pronounced in reduc-
ing pseudotype virus infectivity, suggesting that virus
entry is dependent on low-pH-induced alterations in en-
velope conformation. Earlier studies suggested the im-
portance of the cytoplasmic domain and transmembrane
domain of VSV G for the incorporation of foreign enve-
lope proteins into VSV (Owens and Rose, 1993; Schnell et
al., 1996). For VSV G, the fusion peptide appears to reside
at an internal location of the protein between amino
acids 117 and 137; the viral G protein also requires some
form of membrane anchoring in order to promote mem-
brane fusion (Cleverley et al., 1998; Odell et al., 1997;
Durrer et al., 1995; Fredericksen and Whitt, 1998; Li et al.,
1993; Zhang and Ghosh, 1994). In our hands, BHK or CHO
cell lines stably transfected with the chimeric E1 or E2
glycoproteins did not exhibit fusion with surrounding
cells or develop large multinucleated giant cells in cul-
ture upon a 15-min exposure to a low pH ranging be-
tween 4.5 and 6.5 (unpublished data). Thus, neither of
these two chimeric proteins on cell surface appears to
be present in a fusion competent form. Our data clearly
indicate independent recognition of cell surface recep-
tors by the chimeric glycoproteins on pseudotype virus.
However, we cannot exclude the possibility of any influ-
ence of the transmembrane domain and cytoplasmic tail
present from VSV G in context of the chimeric glycopro-
teins for fusogenic activity, and this remains to be eluci-
dated.
Mammals have evolved at least two mechanisms for
recognizing terminal mannose residues. These are com-
ROLE OF HCV GLYCOPROTEIposed of a mannose receptor located on the surface of
macrophages and a mannose binding-protein found inplasma and secreted by hepatocytes which may play a
role in host recognition of non-self organisms (reviewed
by Ezekowitz and Stahl, 1988). Comparison of the fre-
quency of MBP mutations in patients with acute, self-
limiting HBV infection shows a significant difference in
allele frequencies (Thomas et al., 1996) and genetic sus-
ceptibility to the most adverse outcomes of infection
(Thursz and Thomas, 1997). Our experimental results do
not suggest a direct role for MBP in the neutralization of
pseudotype virus infectivity, likely due to a lack of suit-
able binding sites on HCV E1 or E2. In the present study,
we have used other potential viral ligands to study the
inhibition of pseudotype virus infectivity. A lower dose of
Con A exhibited an increase in pseudotype virus infec-
tivity in human cells (HepG2 and MCF7), while at higher
concentrations pseudotype virus infectivity was neutral-
ized in a dose-dependent manner. Lectins are multiva-
lent molecules and may cross-link viruses with mem-
branes of different cell types (Sharon, 1984; Sharon and
Lis, 1989). The fact that HCV presents multiple high
mannose/hybrid type glycans (Sato et al., 1993) and that
Con A has the ability to form multimers with these forms
of glycans (Derewenda et al., 1989) leads to the specu-
lation that a ligand bridge is formed between HCV enve-
lope glycoproteins and the plasma membrane to en-
hance the proximity of the virus to its cellular receptor.
While at higher concentration, Con A readily hinders
virus attachment due to steric hindrance or alteration of
binding property of the HCV envelope glycoproteins. It is
important to mention that immunized chimpanzee sera to
a baculovirus- or yeast-derived E1/E2 complex failed to
exhibit a detectable pseudotype virus neutralization titer
(Lagging et al., 1998), as these antigens may present
different glycosylated forms of the HCV envelope pro-
teins. High titers of antibody inhibiting the binding of the
envelope to human cells have been suggested to corre-
late with spontaneous resolution of chronic hepatitis C
(Ishii et al., 1998). Recombinant E1/E2 or E2 expressed in
mammalian cells, but not in yeast, can bind human cells
and chimpanzees immunized with envelope proteins ex-
pressed in insect cells or yeast exhibit a low or unde-
tectable level of neutralization of binding antibodies
(Choo et al., 1994; Rosa et al., 1996). Together these
results suggest that binding of the antibodies to discrete
linear epitopes on HCV E1 or E2 may not be sufficient to
perturb their functional activities with the cell surface
proteins or receptors for virus entry. Decoration of the
HCV E1 and E2 protein backbone by complex sugar
moieties is likely to involve these two viral glycoproteins
in unique interactions with the cell surface and may
protect the viral envelope from immune attack.
Partial inhibition of E1 or E2 pseudotype virus entry by
heparin further suggested that the complex proteoglycan
serves as a class of cell surface molecule to facilitate
221PSEUDOTYPE VIRUS ENTRYvirus infection into mammalian cells. Glycosaminogly-








































































































ASU, Aseveral human pathogens (Spear, 1993; Herold et al.,
1995; Chen et al., 1997; Boyle and Compton, 1998). How-
ever, binding of virus to cells is not sufficient to mediate
penetration (Montgomery et al., 1996). Thus heparin-like
oieties present on the cell surface may serve as an
nitial attachment vector for HCV, and additional recep-
ors may work for virus entry. LDL-R for E1 and CD81 for
2 appear to play a role in pseudotype virus infectivity.
owever, other putative receptors (recombinant EGF-R
nd TNF-R) and receptor blockers (a2-M*, EGF, trans-
errin, and lactoferrin) did not inhibit E1 or E2 pseudotype
irus entry to any significant degree in our experimental
ystem (unpublished observation). These findings further
uggest that unique functional features may exist in
onjunction with the shared properties of HCV E1 and E2
lycoproteins which allow them to interact with the cell
urface to facilitate virus entry. A recent study demon-
trated that wild-type Sendai virus is able to efficiently
se two distinct receptors, the asialoglycoprotein recep-
or (ASGP-R) and the sialic-acid-containing gangliosides
Bitzer et al., 1997). ASGP-R itself contains carbohydrate
ide chains which display terminal galactose residues
ith exogenous ligands for the ASGP-R binding sites.
he envelope proteins (Erns and E2) of classical swine
ever virus interact with different receptors (Hulst and
oormann, 1997). On the other hand, the G protein in a
emperature-sensitive mutant of respiratory syncytial vi-
us is not essential to initiate infection (Karon et al.,
997). Thus, virus envelope glycoproteins may possess
ersatility in their recognition of cell surface molecules to
acilitate entry into mammalian cells.
An intracellular association of HCV E1 and E2 has
een suggested from a number of in vitro studies follow-
ng expression of HCV partial genomic regions as re-
ombinant proteins. E1 and E2 are suggested to physi-
ally form oligomeric structures associated by noncova-
ent or disulfide bridges (Grakoui et al., 1993; Lanford et
l., 1993; Ralston et al., 1993; Deleersnyder et al., 1997).
owever, disulfide bonds are not required either to allow
ssociation between the proteins or to stabilize the
1–E2 complexes (Patel et al., 1999). It is hypothesized,
ut not proven, that the noncovalent heterodimers rep-
esent the functional subunit of HCV glycoproteins,
hereas the disulfide-linked aggregates are formed by
isfolded proteins (reviewed in Choukhi et al., 1999;
eleersnyder et al., 1997). A different study suggested
hat physical association between the core protein and
1 glycoprotein, most likely taking place in the ER mem-
rane, may have a role in virus morphogenesis (Lo et al.,
996). Physical interactions among core, E1, and E2 have
lso been observed in a different study using a recom-
inant baculovirus expressing HCV structural proteins
Baumert et al., 1998). The C-terminal (Selby et al., 1994)
nd the N-terminal regions of E2 (Yi et al., 1997) may
222 MEYER, Bontribute to E1 binding, and glycosylation does not
ppear to have a critical role in heteromeric interaction.
t
mlthough we truncated small C-terminal portions of the
1 and E2 glycoproteins for generation of the chimeric
ene constructs, the interacting regions of E2 believed to
e necessary for association with E1 were present. In
ur pseudotype virus system, it is difficult to determine
he relevance of the functional role of both E1 and E2
ogether, even if they were to form a heterodimeric com-
lex. The individual glycoproteins might not be ex-
ressed at optimal stoichiometric ratios for a functional
ssociation between E1 and E2, and as a result the
ndependent functional role of the individual glycopro-
eins present in excess would interact with the cell sur-
ace and lead to a potential misinterpretation of the
esults. Regardless of this problem, we undertook stud-
es for the generation of pseudotype virus from cells
oexpressing chimeric E1 and E2 glycoproteins. VSV
seudotype virus generated from at least three indepen-
ent preparations exhibited plaque titers within a varia-
ion of 60.5-fold when compared to the titers of
seudotype virus generated from E1 or E2 expressed as
single glycoprotein in transfected mammalian cells
unpublished observations). Since a significant augmen-
ation of infectivity was not observed in pseudotypes
enerated by coexpression of E1 and E2, we tentatively
onclude that the cell surface interactions observed in
his system may not be significantly altered by coexpres-
ion of the two glycoproteins. Additionally, expression of
1 and E2 in a single pseudotype virus would not allow
or the elucidation of the separable properties of the
nvelope glycoproteins as observed here.
The pseudotype virus chosen for this study allows for
he determination of a number of glycoprotein-specific
nteractions with mammalian cells for entry by using a
urrogate virus. However, we cannot exclude the possi-
ility that the chimeric glycoproteins used to generate
he pseudotype virus may not mimic HCV infection of
ammalian cells. The results of this study may lead us to
onclude that the chimeric E1 and E2 glycoproteins ex-
ibit temperature-dependent interactions with mamma-
ian cells, higher infectivity in cells of human origin,
olerance to low pH exposure, and inhibition of
seudotype virus infectivity with an increase in endoso-
al pH. With the proposed roles of a number of cellular
igands in virus attachment and penetration, it is not
bvious that HCV E1 and E2 exhibit criteria of singular
eceptor–ligand interactions, such as saturability, speci-
icity, and induction of a measurable physiological re-
ponse. Nevertheless, the study presented here is an
mportant step toward demonstrating the role of heparin,
D81, and LDL-R with regard to the individual glycopro-
eins and the potential for subsequent HCV entry into
ammalian cells. A further understanding of HCV entry
nd strategies appropriate for mimicking cellular recep-
ND RAYor(s) may help in the development of new therapeutic












































































NS INMATERIALS AND METHODS
VSV/HCV pseudotype virus and plaque assay
The generation of VSV/HCV pseudotype virus from
chimeric gene constructs encoding the putative ectodo-
mains of HCV E1 or E2 envelope glycoproteins and the
transmembrane domain and cytoplasmic tail of vesicular
stomatitis virus G protein using a temperature sensitive
mutant of VSV (VSV ts045) in serum-free medium has
been described earlier (Lagging et al., 1998). During
preparation of the virus stock, wild-type VSV G (Gwt)
loned into pcDNA3 mammalian expression vector un-
er the control of T7 promoter (positive control) or empty
cDNA3 vector DNA (negative control) was also used
nder similar transfection conditions for the generation
f pseudotype virus. Plaques were not observed in cul-
ure fluid derived from empty vector transfected controls
nder identical assay conditions. The titer in the culture
luid of the nonpseudotype VSV/Gwt (positive control)
enerated by transfection with Gwt was greater than that
f the E1 or E2 pseudotype virus, as noted earlier (Lag-
ing et al., 1998). The VSV/HCV E1 or E2 virus generated
n baby hamster kidney epithelial cells was treated with
ntibodies to VSV-G (kindly provided by Randall J.
wens, St. Jude Childrens Hospital, TN) and vaccinia
irus (kindly provided by B. Moss, NIH, MD) at 37°C for
h, aliquoted, and kept frozen until used. A plaque assay
or virus infectivity and its inhibition was determined in
HK and two different human epithelial cells (human
reast carcinoma cells, MCF7; and human hepatoma
ells, HepG2) at 32°C (permissive temperature for the
SVts045 mutant) in serum-free medium following a sim-
lar procedure (Lagging et al., 1998) using different pH of
he agar overlay. HepG2 cells required a slightly higher
H (;7.6), compared to BHK cells (;7.2) for the agar
verlay. This appears to be due to a lowering of pH by
epG2 cells during incubation, which hinders virus
rowth for plaque formation. This standardized assay
ondition allowed us to more accurately determine
seudotype virus titer in HepG2 cells. However, plaque
ssay on BHK and MCF7 cells required a similar pH
ondition of the agar overlay. To analyze the effect that
lockage of a specific receptor had on individual
seudotype infectivity, specific ligands were adsorbed to
he cell monolayers at ;4°C and all subsequent steps
ere carried out at this temperature. The cell monolayer
as washed with cold serum-free DMEM and incubated
or 30 min on ice prior to use. Ice-cold reagents were
dded on cells in an ice box for adsorption at ;4°C,
ollowed by the addition of cold virus inoculum. The cell
onolayer was washed several times with ice-cold
MEM and incubated with serum-free warm DMEM for
h at 32 or 37°C. A temperature range between 32 and
7°C for virus adsorption did not have a detectable effect
ROLE OF HCV GLYCOPROTEIn the virus titer in any of the cell lines tested. Where
pplicable, this alteration in temperature also did notppear to effect the outcome of any experimental proce-
ures. Medium was discarded before the addition of an
gar overlay for incubation at 32°C for 20 to 30 h. Occa-
ional pH alterations and clumping were observed using
epG2 cells with an agar overlay in the plaque assay.
his led to interference in distinct plaque formation.
owever, results from BHK and MCF7 cells were very
onsistent and appeared to present an attractive alter-
ative as cell substrates for the pseudotype plaque as-
ay. Large plaque formation of the pseudotype virus,
articularly on BHK cells, offered an advantage for an
asy and convenient readout of the assays. All results
ere correlated on each of the three cell lines, and
ariations were minimal.
epletion of divalent cations
The cell monolayer was briefly washed with Ca21/
Mg21-free HEPES-buffered saline solution (HBSS), fol-
owed by incubation with HBSS containing 0.5, 1, or 2 mM
GTA for 5 min at room temperature. Virus inoculum in
a21/Mg21-free HBSS, supplemented with EGTA, was
dded to the cell monolayer and incubated for 20 min.
noculum was removed and the cell monolayer was
ashed with HBSS, and overlaid with agar as described
Lagging et al., 1998).
Effect of pH on pseudotype virus titer
Virus stocks of known titer were treated in medium
containing HEPES–HCl buffer of different pH values for
60 s before adding 1 M NaOH to bring the medium to
neutral pH (McClure et al., 1990). Treated virus was
added to the cell monolayer to determine plaque num-
bers compared to an untreated control. For treatment
with an endosomal pH modulator, cells were treated with
ammonium chloride, bafilomycin A1, or concanamycin A
(Sigma Chemical Company, St. Louis, MO) as described
earlier (McClure et al., 1990; Martinez et al., 1996). A
stock solution of bafilomycin A1 (30 mM) was prepared in
DMSO and diluted in the culture medium immediately
before use. Briefly, cells were treated for 30 min with
NaHCO3-free Dulbecco’s essential medium (DMEM),
upplemented with 25 mM HEPES buffer, pH 7.6, and the
ndicated doses of ammonium chloride. Alternatively,
ells were separately treated with bafilomycin A1 or
oncanamycin A for 10 min prior to pseudotype virus
nfection. The indicated reagents were also present in
he virus inoculum during the 3-h adsorption period. The
ell culture plate was sealed with parafilm and incubated
t 32°C without CO2 during this period. Control experi-
ments were done with VSVts045 in the same medium or
in the absence of endosomal pH modulators. At the end
of the incubation period, cells were washed with DMEM


















Heparin, heparan sulfate, dextran sulfate, and suramin
(Sigma) were dissolved in DMEM, filter sterilized, and
used at the indicated doses for virus neutralization. Virus
was incubated with the indicated glycosaminoglycans at
32°C for 1 h and added to the cell monolayer for plaque
assay as described earlier (Lagging et al., 1998). Hepa-
rinase (Sigma) was added onto the cell monolayer and
incubated for 30 min prior to and during adsorption of
virus followed by an overlay for plaque assay.
Other reagents and cell surface blocking assay
Concanavalin A, galanthus nivalis agglutinin, and phy-
tohemagglutinin P (Sigma) were used to determine the
role of the carbohydrate components of HCV E1 or E2 in
pseudotype virus infectivity. Purified recombinant human
mannose binding protein, kindly provided by R. Alan B.
Ezekowitz (Harvard Medical School, MA) (Super et al.,
1992), alone or together with guinea pig complement
(Sigma) was also used to determine their role in the
inhibition of pseudotype virus plaque formation. Mono-
clonal antibodies to human CD81 (Pharmingen, CA) and
low-density lipoprotein receptor (LDL-R) were used to
block their respective cell surface receptor activities.
Cells secreting IgG-C7 monoclonal antibody to LDL-R
(ATCC) were grown in serum-free medium (BRL). IgG
was purified by protein A–Sepharose 4B column (Phar-
macia, NJ) as described earlier (Beisiegel et al., 1981)
and used at 4°C to block receptor activity. For blocking
assay, cells grown in six-well plates were cooled to 4°C
and unbound cells were removed by rinsing three times
with ice-cold DMEM. LDL (Sigma), vLDL (CalBiochem,
San Diego, CA), or purified IgG-C7 was added to each
well at various concentrations in cold medium, and cells
were incubated for 30 min on ice. A predetermined titer
of pseudotype virus inoculum was added to each well
and incubated at 4°C for 30 min with intermittent tilting.
Unbound ligands from each well were removed by rins-
ing three times with ice-cold DMEM. Cells were then
incubated at 32°C for 30 min before the addition of an
agar overlay for plaque formation. For CD81 blocking,
human epithelial cells were incubated with the specific
monoclonal antibody at 32°C for 1 h. Cells were washed
and treated with virus for plaque assay.
A recombinant baculovirus expressing the LDL recep-
tor (LDL-R354) was kindly provided by Alan D. Attie (Uni-
versity of Wisconsin–Madison). The recombinant protein
is secreted from cells and is able to bind with high
affinity to LDL and calcium, and the ligand-binding do-
main of the LDL-receptor folds into a functionally active
protein (Dirlam et al., 1996). The secreted LDL-R354 pro-
tein was purified using a DEAE–Sepharose column as
already described (Dirlam et al., 1996). The purified pro-
24 MEYER, Btein was examined by silver staining and immunoblot
analysis, and the protein content was estimated (Bio-Rad) prior to use in pseudotype virus neutralization as-
say. Virus was incubated with different concentrations of
LDL-R354 (5–25 mg/ml) at 32 or 37°C prior to and during
dsorption onto the cell monolayer.
A human CD81 cDNA clone was kindly provided by
oshana Levy (Stanford University School of Medicine,
tanford, CA). The cDNA was cloned into pPROEXHTa
Life Technologies, Rockville, MD) for expression of
D81 as a fusion protein with a 63 histidine affinity tag
or rapid purification. Transformed bacteria were induced
ith IPTG and the recombinant protein was purified in a
i-NTA resin column following manufacturer’s procedure
Life Technologies). Protein contents of the purified CD81
ere estimated (Bio-Rad) and analyzed by SDS–PAGE
ollowed by silver staining. Pseudotype virus was incu-
ated with increasing concentrations of recombinant
D81 (5–25 mg/ml) at 32 or 37°C for neutralization of
nfectivity before addition onto the cell monolayer for
laque assay.
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